By 2023, the global Frontotemporal Dementia Management Market is projected to reach US$ 10 million, with an expected CAGR of 6% from 2023 to 2033 resulting in an accumulated market value of US$ 17.91 million. From 2018 to 2022, the market registered a CAGR of 4%.
For In-depth insights, Download Sample Copy@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16489
Neurodegenerative diseases such as frontotemporal disorder, Alzheimer’s, and dementia affect the population aged 65 years and above. Non-profit organizations such as the Association for Frontotemporal Degeneration (AFTD), Alzheimer Discovery Foundation (ADDF), Bluefield Project Organization, Tau Consortium Organization, and CurePSP, Inc. promote research initiatives in frontotemporal dementia management by supporting clinical trials and preclinical studies for testing new therapeutics that are interventional to slow or stop dementia.
As per the World Health Organization, approximately 50 million people have dementia, with nearly 10 million new cases every year, which is expected to boost industry growth. Although the cause of Frontotemporal dementia is still unknown, it majorly affects individuals between the ages of 40 to 60 and causes serious psychotic episodes and language and communication problems, affecting not just patients but also those around them.
North America is expected to capture a market share of about 25% in the forecast period due to the rising prevalence of the condition in the region, government initiatives, increased number of research partnerships, presence of advanced healthcare facilities, stronger purchasing power for expensive pharmaceuticals, reimbursement regulations, and an expanding patient pool, which are all contributing to the growth of the market in North America.
Contact Us for a Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-16489
Key Takeaways from the Market Study
- From 2018 to 2022, the Frontotemporal Dementia Management market grew at a CAGR of 4%.
- The global Frontotemporal Dementia Management market is expected to grow with a 6% CAGR during 2023 to 2033.
- As of 2033, the Frontotemporal Dementia Management Market is expected to reach US$ 17.91 Million
- According to the FMI analysis, hospitals account for the largest market share.
- North America is expected to possess 25% market share for the Frontotemporal Dementia Management market.
- The Asia Pacific market is predicted to increase significantly throughout the forecast period, with a CAGR of 5% during the forecast period.
“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering Frontotemporal Dementia Management.” says an FMI analyst
Market Competition
Key players in the Frontotemporal Dementia Management market are Celgene Corporation, BlueBird Bio, Protagonist Therapeutics, Agios Pharmaceuticals, Ionis Pharmaceuticals, Vifor Pharma, Sangamo Therapeutics, Orchard Therapeutics, CRISPR Therapeutics, and DisperSol Technologies among other global players.
- In January 2021, LSP, the leading European life sciences investor, and Professor Philip Scheltens, a world-renowned dementia scientist, will launch the LSP Dementia Fund, a fund dedicated to fighting neurodegenerative diseases, in Amsterdam.
- Alzheimer’s Disease International, in collaboration with the Global Coalition on Aging (GCOA) and the Lien Foundation, will launch the third Dementia Innovation Readiness Index in 30 global cities around the world in October 2020.
More Insights Available
Europe is the second-largest frontotemporal dementia treatment market, with countries such as Germany, France, and the United Kingdom leading the way. The European market is expected to grow due to the increasing prevalence of the disease and the growing elderly population.
The Asia-Pacific region is expected to be the fastest-growing market for frontotemporal dementia treatment due to the large population and growing healthcare infrastructure. Japan is the largest market for FTD treatment in this region, but countries such as China and India are expected to have significant growth potential in the future.
Visit for Customization@ https://www.futuremarketinsights.com/customization-available/rep-gb-16489
Key Segments Profiled in the Frontotemporal Dementia Management Industry Survey
Drug Class Type:
- Antidepressants
- Fluoxetine
- Fluvoxamine
- Sertraline
- Paroxetine
- Citalopram
- Bupropion
- Mirtazapine
- Antipsychotics
- Olanzapine
- Quetiapine
- Ziprasidone
- Aripiprazole
- Risperidone
- Paliperidone
End-Users:
- Hospitals
- Specialty clinics
- Others
Distribution Channel:
- Hospital Pharmacy
- Drug store
- Retail Pharmacy
- Online Pharmacy
- Others
About Future Market Insights, Inc.
Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs